Clinical Trials Logo

Cancer of Liver clinical trials

View clinical trials related to Cancer of Liver.

Filter by:

NCT ID: NCT03766776 Not yet recruiting - Cancer of Liver Clinical Trials

Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

ATAHC
Start date: December 31, 2018
Phase: N/A
Study type: Interventional

This is a prospective, one-arm, exploratory clinical study to observe and evaluate the efficacy and safety of Anlotinib hydrochloride capsules in patients with advanced liver cancer.

NCT ID: NCT03607643 Not yet recruiting - Clinical trials for Glioblastoma Multiforme

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Start date: January 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI Malignancies

NCT ID: NCT03452774 Recruiting - Breast Cancer Clinical Trials

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

NCT ID: NCT03347162 Active, not recruiting - Cancer Clinical Trials

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Start date: December 1, 2017
Phase:
Study type: Observational

PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory. GI-HEP: Patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.

NCT ID: NCT03323996 Recruiting - Diabetes Clinical Trials

Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients

METIS
Start date: July 26, 2017
Phase: N/A
Study type: Observational

This study aims to describe the impact of a training in therapeutic education on the relation between a caregiver and his/her patients. Subjects are recruited among health professionals attending a training in therapeutic education. Then they are asked to identify up to 5 of their patients to be contacted by the researcher for an interview. Individual semi-structured interviews are conducted with 20 duo "caregivers / patients" before the training, 1 month and 6 months after the training.

NCT ID: NCT03299036 Completed - Cancer of Liver Clinical Trials

Drug-loadable(T-ACE Beads)for Hepatoma Embolization Therapy

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere (T-ACE Beads with doxorubicin) interventional therapy for patients with liver cancer

NCT ID: NCT03133286 Recruiting - Cancer Clinical Trials

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

RADIANT
Start date: April 6, 2017
Phase:
Study type: Observational

Collect blood samples and associated clinical data prior to, during, and post radiation treatment.

NCT ID: NCT02825550 Completed - Cancer of Liver Clinical Trials

Taiwan ACE Beads for Hepatoma Embolization Therapy

Start date: April 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere (T-ACE Beads) interventional therapy for patients with liver cancer

NCT ID: NCT02145559 Completed - Lymphoma Clinical Trials

A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors

Start date: April 2014
Phase: Phase 1
Study type: Interventional

Given the role of mTOR signaling and probable synergistic activity of combining sirolimus and metformin in patients with advanced solid tumors, the investigators hypothesize that: 1. The combination of metformin plus sirolimus will result in reduction of p4EBP1, p70S6K and pAKT more than sirolimus alone in peripheral blood T cells (PBTC). 2. The combination of metformin plus sirolimus will result in decreased levels of serum biomarkers including fasting insulin, C-peptide, glucose, triglycerides, LDH, IGF-1, IGF-1R, IGF-BP and leptin, but an increase in adiponectin in peripheral blood. 3. Expression of active forms of AMPK, mTOR, PI3K, PTEN loss, AKT, LKB1, P62, LC3, and/or ULK1 in the tumor tissue (original pathology) will be predictive of response to combination therapy. This will be an exploratory hypothesis for this study. 4. Sirolimus induced toxicity, especially hyperglycemia and hypertriglyceridemia, will be mitigated by combining sirolimus with metformin. 5. Metformin plus sirolimus will have promising anti-cancer activity and this activity will correlate with decreases in the above biomarkers. This will be an exploratory hypothesis for this study.

NCT ID: NCT02044224 Completed - Cancer of Pancreas Clinical Trials

Effects of Dexmedetomidine During IRE Procedures for Solid Tumours

Start date: January 2014
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate effects of dexmedetomidine on anaesthesia during IRE procedures for solid tumours